This early-phase trial tests a personalized oral DNA cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs in 20 adults with solid tumors. The vaccine is designed to target unique markers on each patient's cancer. The study aims to check safety and whether the…
Phase: PHASE1, PHASE2 • Sponsor: NEC Bio B.V • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC